stockrow
Friday 6 November 2026
Export VREX’s income statement to Excel — free account
VAREX IMAGING
VREX Healthcare Medical Devices
VAREX IMAGING’s revenue for fiscal 2025 (year ended September 2025) was $844.6 million, up 4.14% from fiscal 2024.
- Revenue
- +3.69%
- EPS
- +117.2%
- Free cash flow
- +757.1%
- Total debt
- −5.55%
Quarter to June 2026, against a year earlier
18.44
0.00
0.00%
Follow VREX
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
19.68 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.51 | 0.52 | 0.57 | 0.61 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 27.31 | |
P/Operating CF |
20.91 | (297.08) | (30.25) | 64.98 | |
P/B ratio |
0.86 | 0.91 | 0.99 | 1.06 | |
Price to Tangible BV |
1.46 | 1.61 | 1.75 | 1.87 | |
EV/Sales |
0.79 | 0.82 | 0.85 | 0.86 | |
EV/EBITDA |
6.80 | 7.70 | 7.32 | 7.56 | |
EV/Operating CF |
60.80 | (352.46) | 45.28 | 17.40 | |
EV/FCF |
(34.01) | (22.89) | (54.81) | 38.60 | |
Quick Ratio |
1.30 | 1.21 | 1.67 | 1.67 | |
Current Ratio |
3.38 | 3.20 | 3.89 | 3.43 | |
Net Debt/EBITDA |
8.24 | 12.06 | 10.66 | 7.96 | |
Debt/Assets |
31.55% | 31.91% | 33.48% | 33.19% | |
Debt/Equity |
0.68 | 0.71 | 0.75 | 0.76 | |
Asset Turnover |
0.80 | 0.70 | 0.70 | 0.73 | |
Operating CF/Net income |
1.34 | 0.19 | (7.00) | 0.65 | |
Capex/Depreciation |
(1.23) | (0.87) | (1.47) | (0.79) | |
Interest Coverage |
3.93 | 0.84 | 1.95 | 2.48 | |
Research and Development Expense of Revenue |
11.07% | 10.28% | 10.35% | 10.57% | |
Selling, General and Administrative Expense of Revenue |
14.54% | 16.67% | 15.60% | 14.85% | |
Intangible Assets out of Total Assets |
0.19 | 0.19 | 0.19 | 0.19 | |
Share Based Compensation of Revenue |
1.81% | 1.85% | 1.81% | 1.49% | |
Graham Net Nets |
0.10 | 0.05 | 0.05 | 0.04 | |
Graham Number |
12.03 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
5.08% | (18.76%) | (13.99%) | (13.71%) | |
Free Cash Flow Yield |
(4.60%) | (6.91%) | (2.73%) | 3.66% | |
Revenue per Share |
5.00 | 5.14 | 5.01 | 5.53 | |
Operating CF per Share |
0.50 | (0.04) | (0.39) | 0.19 | |
Capex per Share |
(0.21) | (0.15) | (0.26) | (0.14) | |
Free Cash Flow per Share |
0.29 | (0.18) | (0.64) | 0.06 | |
Cash per Share |
2.36 | 2.10 | 3.00 | 3.75 | |
Shareholders Equity per Share |
12.13 | 11.62 | 11.74 | 11.75 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
12.13 | 11.62 | 11.74 | 11.75 | |
Free Cash Flow |
12.00 | (7.70) | (26.80) | 2.30 | |
Working Capital |
445.70 | 430.30 | 470.60 | 454.60 | |
Capital Expenditures |
(9.00) | (6.20) | (10.70) | (5.60) | |
Net Current Asset Value |
43.60 | 24.30 | 26.40 | 21.00 | |
EV/EBIT |
9.52 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.03 | 0.05 | 0.02 | |
Price to Operating Income |
6.08 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
140.85 | 146.90 | 142.30 | 157.15 | |
Average Payables |
77.10 | 83.60 | 72.25 | 64.50 | |
Average Inventory |
322.90 | 315.70 | 303.95 | 282.10 | |
Average Assets |
1,086.70 | 1,223.50 | 1,215.10 | 1,160.50 | |
Average Common Equity |
490.00 | 526.00 | 522.50 | 514.90 |
Columns are period end dates · fundamentals updated 25 Oct 2026